Docket No.: TRIUS.002NP

Page 1 of 1

# Please Direct All Correspondence to Customer Number 20995

JUL 0 9 2008

### **TRANSMITTAL**

**Applicant** 

Jae Rhee et al.

Appl. No.

: 10/596,412

Filed

June 13, 2006

For

NOVEL OXAZOLIDINONE

**DERVIATIVES** 

Examiner

: Patricia L. Morris

Group Art Unit

1625

Certificate of Mailing

I hereby certify that this correspondence and all marked attachments are being deposited with the United States Postal Service as first-class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA, 22313, on

July 7, 2008

(Date)

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Sir:

Transmitted herewith for filing in the above-identified application are the following enclosures:

- (X) A copy of Specific Power of Attorney with Revocation in one page.
- (X) A Statement Under 37 C.F.R. § 3.73 (b) in or page.
- (X) Please charge any additional fees, including any fees for additional extension of time, or credit overpayment to Deposit Account No. 11-1410.

Joseph J. Mallon

Registration No. 39,287

Attorney of Record

Customer No. 20,995

(619) 235-8550

5613886/hc 070708



Docket No.:

TRIUS.002NP

App. No.: 10/596,412

Page 1 of 1

## Please Direct All Correspondence to Customer Number 20995

#### SPECIFIC POWER OF ATTORNEY WITH REVOCATION

**Applicant** 

Jae Rhee, et al.

App. No.

10/596,412

Filed

June 13, 2006

For

NOVEL OXAZOLIDINONE DERVIATIVES

Examiner

Patricia L. Morris

Art Unit

1625

Conf. #

6355

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

#### Dear Sir:

The undersigned is an empowered representative of the Assignee. As of the exection date of the Assignment or the execution date set forth below, whichever is later, the undersigned he eby revokes any previous powers of attorney in the subject application, and hereby appoints the r gistrants of Knobbe, Martens, Olson & Bear, LLP, Customer No. 20995, as its attorneys with full power of substitution and revocation to prosecute this application and to transact all business in the U.S. Patent and Trademark Office connected herewith. This appointment is to be to the exclusion of the inventor(s) and his attorney(s) in accordance with the provisions of 37 CFR § 3.71.

Attached is a Statement Under 37 CFR § 3.73(b), signed by a registrant of Knob e, Martens, Olson & Bear, LLP, setting forth a full chain of title for the subject application owned by the Assignee named below.

Please recognize or change the correspondence address for the application iden fied in the attached Statement to Customer No. 20995.

By:

Name:

Title:

Assignee:

DONG-A PHARMACEUTICALS CO. LTD.

Address:

252 Yongdu-dong, Dongdaemun-gu

Seoul, Republic of Korea

5596995/dp 070108

Docket No.: TRIUS.002NP

# STATEMENT UNDER 37 CFR § 3.73(b) ESTABLISHMENT OF ASSIGNEE

Applicant

: Jae Rhee, et al.

App. No.

: 10/596,412

Filed

June 13, 2006

For

: NOVEL OXAZOLIDINONE DERVIATIVES

Examiner

Patricia L. Morris

Group Art Unit

1625

Commissioner for Patents

P.O. Box 1450

Alexandria, VA 22313-1450

Dear Sir:

This document is being filed with a copy of a Power of Attorney signed by the Assignee. This Statement sets forth the chain of title of the above-identified application.

DONG-A PHARMACEUTICALS CO. LTD., a Korean Corporation, is the Assignee of the entire right, title, and interest of the above-referenced application by virtue of:

The Assignment from the inventors to the Assignee recorded in the United States

Patent and Trademark Office on June 13, 2006, at Reel 017768, and Frame 0119.

The undersigned is an agent of Customer Number 20995 and is authorized to act on behalf of the Assignee. Please recognize or change the correspondence address for the above-identified application to Customer No. 20995.

Respectfully submitted,

KNOBBE, MARTENS, OLSON & BEAR, LLP

Dated: 7 July 2008

Registration No. 39,287

Attorney of Record Customer No. 20995

(619) 235-8550

5613603/hc

070708